In accordance with the Colorado Wholesale Acquisition Cost Disclosure Law (Colorado Revised Statutes Section 12-42.5-308), Partner Therapeutics is disclosing to authorized prescribers of prescription drugs in Colorado certain required wholesale acquisition cost (WAC) pricing information for Partner Therapeutics-marketed products.
Please choose a product from the list, and select “WAC Information” below.
LEUKINE® (sargramostim) for Injection, for Subcutaneous or Intravenous Use
BIZENGRI® (zenocutuzumab – zbco) Injection for IV Use
The listing of generic products in the disclosure forms does not imply that such products are interchangeable with the Partner Therapeutics-marketed product or have the same efficacy or safety. Please refer to each product’s U.S. Food and Drug Administration (FDA)-approved prescribing information for further information. To access approved prescribing information for Partner Therapeutics-marketed products in the US, visit https://www.partnertx.com/us/about/product.
The prescribing information approved by the FDA must continue to guide appropriate use of Partner Therapeutics medicines. The intent of this website is only to provide wholesale acquisition price information to authorized prescribers of prescription drugs in Colorado in accordance with Colorado law. For more detailed information or healthcare advice, members of the public should consult their healthcare professionals.